Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma

Nader, Manar A.

doi:10.1016/j.intimp.2015.08.043

Cited by 31 publications

(22 citation statements)

References 56 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Provocative studies have shown the potential of metformin, DPP-4 inhibitors, and statins in treating asthma (Huang et al, 2011; Li et al, 2016; Nader, 2015; Zeki et al, 2013). And while the GLP-1 pathway may also be effective, it is unclear which phenotypes of asthma it may help.…”

Section: Resultsmentioning

confidence: 99%

“…DPP-4 appears to activate pro-inflammatory pathways (MAPK and NF-κB) and may also increase generation of reactive oxygen species, AGEs, and RAGE gene expression (Ishibashi et al, 2013; Wronkowitz et al, 2014). Although upregulated DPP-4 may act to downregulate GLP-1’s benefits, the evidence for the use of DPP-4 inhibition in asthma is conflicting (Nader, 2015; Nieto-Fontarigo et al, 2016). …”

Section: Glucagon-like Peptide 1 and The Lungmentioning

confidence: 99%

See 1 more Smart Citation

Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma

Nguyen

Linderholm

Haczku

et al. 2017

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Alterations in arginine metabolism and accelerated formation of advanced glycation end-products (AGEs), crucial mechanisms in obesity-related asthma, can be modulated by glucagon-like peptide 1 (GLP-1). L-arginine dysregulation in obesity promotes inflammation and bronchoconstriction. Prolonged hyperglycemia, dyslipidemia, and oxidative stress leads to production of AGEs, that bind to their receptor (RAGE) further potentiating inflammation. By binding to its widely distributed receptor, GLP-1 blunts the effects of RAGE activation and arginine dysregulation. The GLP-1 pathway, while comprehensively studied in the endocrine and cardiovascular literature, is under-recognized in pulmonary research. Insights into GLP-1 and the lung may lead to novel treatments for obesity-related asthma.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Glucagon-like Peptide 1 and The Lungmentioning

confidence: 99%

Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma

Nguyen

Linderholm

Haczku

et al. 2017

Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Nader et al . reported that sitagliptin, a DPP‐4 inhibitor, significantly reduced lung eosinophilia in bronchoalveolar lavage fluid and lung tissue in a murine model of acute allergic asthma, and Nader later also demonstrated that sitagliptin reduced the accumulation of eosinophils in the lungs of a “chronic” murine model of asthma through reductions in interleukin (IL)‐13 and transforming growth factor (TGF)‐β1. IL‐13 and TGF‐β1 are known to increase eosinophil‐recruiting cytokines and eotaxin‐1 production in human airway fibroblasts .…”

Section: Discussionmentioning

confidence: 99%

Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid

Chijiwa

Takeoka

Kamata

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is an acquired autoimmune blistering disease in which autoantibodies against epitopes in the basement membrane zone of the skin such as BP180 or BP230 are produced. Dipeptidyl peptidase (DPP)-4 inhibitors have become commonly used to treat diabetes. As DPP-4 inhibitors are more commonly prescribed for diabetes, BP related to DPP-4 inhibitors has been reported and has attracted attention. Therefore, we retrospectively investigated patients who were diagnosed with BP in order to examine characteristics of DPP-4 inhibitor-related BP (nine patients; median age, 85 years) in comparison with non-DPP-4 inhibitor-related BP (21; median age, 85 years). There was no significant difference in Bullous Pemphigoid Disease Area Index between DPP-4 inhibitor-related BP patients and non-DPP-4 inhibitor-related BP patients, except for erosions/blisters score in mucosa. Laboratory tests revealed no significant differences between DPP-4 inhibitor-related BP patients and non-DPP-4 inhibitor-related BP patients in total white blood cell count, eosinophil count, neutrophil count and the titer of anti-BP180 antibody. The number of eosinophils infiltrating into the skin was significantly lower in patients with DPP4 inhibitor-related BP than in patients with non-DPP4 inhibitor-related BP. Our results showed that DPP-4 inhibitor-related BP has some distinct pathological characteristics from BP not associated with DPP-4 inhibitor.

show abstract

“… 9 Other research, though, showed that DPP-4 inhibition led to reduced airway inflammation. 10 Immunohistochemistry techniques showed DPP-4 staining in airway biopsies of asthma patients. Shiobura et al found greater expression of DPP-4 in bronchial epithelial cells, 11 but van der Velden et al did not confirm this finding in a similar study.…”

Section: Introductionmentioning

confidence: 99%

The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship

Colice

Price

Verdier

et al. 2017

POR

View full text Add to dashboard Cite

RationaleDPP-4 may regulate immunological pathways implicated in asthma. Assessing whether DPP-4 inhibitor (DPP-4i) use might affect asthma control is clinically important because DPP-4i use in type 2 diabetes mellitus management (T2DM) is increasing. This study evaluated associations between DPP-4i use and asthma control.MethodsThis was a retrospective, observational, matched cohort study using administrative claims in the MarketScan® Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare Supplemental) databases. Adult asthma patients initiating an oral DPP-4i or a non-DPP-4i between November 1, 2006 and March 31, 2014 were included. Patients were followed for asthma-related outcomes for 12 months after initiation of the antidiabetes medication. Outcomes included risk-domain asthma control (RDAC), defined as no asthma hospitalizations, no lower respiratory tract infections, and no oral corticosteroid (OCS) prescriptions; overall asthma control (RDAC criteria plus limited short-acting beta agonist use); treatment stability (RDAC criteria plus no increase of ≥50% in inhaled corticosteroid dose or addition of other asthma therapy); and severe asthma exacerbation rates (asthma-related hospitalizations, emergency room visits, or acute treatments with OCS). Comparisons were made between two matched cohorts (DPP-4i vs. non-DPP-4i initiators) using multivariable logistic regression and generalized linear modeling. Covariates included baseline demographic and clinical characteristics related to asthma and T2DM.ResultsThe adjusted odds of achieving RDAC (odds ratio [OR]: 1.05; 95% CI: 0.964 to 1.147), overall asthma control (OR: 1.04; 95% CI: 0.956 to 1.135), and treatment stability (OR: 1.04; 95% CI: 0.949 to 1.115) did not differ between the DPP-4i and non-DPP-4i cohorts. A difference was not found between cohorts in severe asthma exacerbation rates during the 12 months following initiation of antidiabetes treatment (mean = 0.32 vs. 0.34 exacerbations per subject-year, respectively; p=0.064).ConclusionAsthma control was similar between patients initiating DPP-4i and non-DPP-4i antidiabetes medications, suggesting no association between DPP-4i use and asthma control.

show abstract

Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma

Cited by 31 publications

References 56 publications

Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma

Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma

Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid

The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship

Contact Info

Product

Resources

About